TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report)’s stock price shot up 31.4% during mid-day trading on Wednesday. The company traded as high as $0.9399 and last traded at $0.7360. 1,810 shares were traded during trading, a decline of 63% from the average session volume of 4,865 shares. The stock had previously closed at $0.56.
TriSalus Life Sciences Stock Up 16.2%
The business’s fifty day moving average is $0.87 and its two-hundred day moving average is $0.97.
Hedge Funds Weigh In On TriSalus Life Sciences
An institutional investor recently bought a new position in TriSalus Life Sciences stock. State Street Corp acquired a new position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 610,963 shares of the company’s stock, valued at approximately $2,780,000.
About TriSalus Life Sciences
TriSalus Life Sciences is a medical technology and therapeutics company focused on improving treatment delivery for patients with solid tumors, particularly tumors in the liver and pancreas. Its approach combines proprietary drug-delivery technology with the development of immunotherapies.
The company’s TriNav® infusion system is designed to deliver therapies into tumors using its Pressure-Enabled Drug Delivery (PEDD) approach. TriSalus is also developing investigational therapies intended to work alongside its delivery platform; these therapies are not established treatments.
TriSalus became a publicly traded company in 2023 through a business combination with MedTech Acquisition Corporation.
See Also
- Five stocks we like better than TriSalus Life Sciences
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
